Molecular Partners (OTCMKTS:MLLCF – Get Free Report) is expected to release its results before the market opens on Tuesday, August 25th. Analysts expect Molecular Partners to post earnings of ($0.4330) per share for the quarter.
Molecular Partners Price Performance
Shares of MLLCF stock opened at $3.80 on Monday. Molecular Partners has a 12-month low of $2.25 and a 12-month high of $4.85. The firm has a 50-day moving average price of $3.89 and a 200 day moving average price of $3.14.
About Molecular Partners
Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich, Switzerland, specializing in the development of novel protein therapeutics based on its proprietary DARPin® (Designed Ankyrin Repeat Proteins) platform. The company’s pipeline focuses on precision molecules engineered for oncology and immuno-inflammatory diseases, as well as antiviral and anti-infective applications. By leveraging the modular nature of DARPin® science, Molecular Partners designs small, highly stable binding proteins that can engage multiple targets simultaneously, potentially improving efficacy and safety profiles over conventional antibody approaches.
Founded in 2004 by Professor Andreas Plückthun at the University of Zurich, Molecular Partners has advanced several clinical-stage candidates through Phase 1 and Phase 2 trials.
Featured Stories
- Five stocks we like better than Molecular Partners
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
